# A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC

> **NCT02392507** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 54 (actual)

## Conditions studied

- Carcinoma, Non-Small Cell Lung Cancer (NSCLC)

## Interventions

- **DRUG:** Necitumumab
- **DRUG:** Nab-Paclitaxel
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT02392507
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-12
- **Primary completion:** 2018-01-29
- **Final completion:** 2019-11-06
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2020-11-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02392507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02392507, "A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02392507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*